EUCTR2007-004876-38-DE进行中（未招募）不适用
An open label multicenter phase 2 study for the initial evaluation of the tolerability of Birch pollen extract in patients suffering from atopic eczema and clinical relevant IgE-mediated sensitization against birch pollen.
ETI Pharma GmbH0 个研究点开始时间: 2007年9月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients of both gender aged from 18 up to 65 years
- •2. Prior to study specific examinations the patient has to give his/her written informed consent
- •3. Women of child-bearing age employing sufficient contraceptive measurements
- •4. Patients have to suffer from atopic eczema
- •5. Patients have to suffer from clinical relevant IgE-mediated sensitisation against birch pollen assessed by:
- •- specific IgE against birch pollen CAP RAST > 3
- •- positive atopy patch test for birch pollen*
- •- positive skin prick test for birch pollen**
- •6. The diagnosis AE has to be verified according to the criteria of Hanifin and Rajka.
- •7. Duration of atopic eczema > 2 years
- •8. Total SCORAD > 25 at Screening Visit
- •* only in selected study centers, optional but not used as inclusion criterion
- •** if not performed within 3 month prior to screening-visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease specific criteria
- •1. The following therapy is not allowed within the last 5 years prior to screening as well as during the study and will prevent the patient from being included into the study:
- •· Specific Immunotherapy with birch pollen
- •2. The following therapy is not allowed within 3 months prior to screening as well as during the study and will prevent the patient from being included into the study:
- •· Photopheresis
- •3. The following medications and therapies are not allowed within the last month prior to screening as well as during the study and will prevent the patient from being included into the study:
- •· Immunosuppressive agents (cyclosporins, mycophenolates)
- •· Systemic corticosteroids others than basic medication Urbason
- •· UV-therapy, tanning
- •4. The following medications and therapies are not allowed during the entire study and will lead to the patient being withdrawn:
- •· b-blocker (locally and systematically)
- •· Treatment with substances interfering with the immune system
- •· Treatment with tranquillizer or psychoactive drugs
- •5. Patients with therapeutically uncontrolled atopic eczema or erythrodermia
- •Patients with other known concomitant diseases / treatments
- •7. Active tuberculosis
- •8. Acute and chronic inflammatory or infectious diseases at the target organ
- •9. Advanced secondary changes at the target organ (e.g. emphysema or bronchiectasis)
- •10. Immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role
- •11. Immune deficiencies
- •12. Uncontrolled asthma, defined as FEV1 or PEF = 70% of predicted normal value
- •13. Any disease which prohibits the use of adrenaline (e.g. hyperthyroidism)
- •14. Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant
- •15. Malignant disease of any kind during the previous 5 years
- •16. Abnormal laboratory parameters and vital signs that could increase the risk to the study participant
- •17. Alcohol, drug or medication abuse within the past year
- •18. Severe psychiatric or neurologic disorders
- •19. Patients who are expected to be non-compliant and/or not co-operative
- •20. Participation in any other clinical study within the last 30 days prior to the start of the study
- •21. Patients who have already participated in this study
- •22. Patients who are employees at the investigational site, relatives or spouses of the investigator
- •23. Any donation of germ cells, blood, organs, or bone marrow during the course of the study
- •24. Patients who are not contractually capable
- •25. Patients who are detained in an institution due to regulatory or judicially instruction
- •Special restrictions for female patients
- •26. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation
- •27. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >4
研究者
相似试验
进行中（未招募）
1 期
A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanomaEUCTR2016-002114-50-SESahlgrenska University Hospital29
进行中（未招募）
1 期
A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancersFollicular or poorly differentiated cancer refractory to radio iodineMedDRA version: 19.1Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003814-15-FRHOSPICES CIVILS DE LYO
进行中（未招募）
不适用
An multicenter open label phase II study to assess the efficiency and safety of APO866 in the treatment patients with refractory or relapsed cutaneous T-cell lymphoma - APO866 for CTCPrimary cutaneous lymphomas are non-Hodgkin lymphomas that present to the skin without evidence of extracutaneous disease at the time of diagnosis. It refers to either to cutaneous T-cell lymphoma (CTCL) or cutaneous B-cell lymphoma (CBCL). The primary cutaneous lymphomas are classified according to the WHO-EORTC classification. CTCL constitutes about 65% of all primary cutaneous lymphomas, of which mycosis fungoides is the most prevalent clinical presentation.MedDRA version: 8.1Level: PTClassification code 10028483EUCTR2005-006157-24-ATTopoTarget A/S25
进行中（未招募）
不适用
A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma - APO866 for CTCPrimary cutaneous lymphomas are non-Hodgkin lymphomas that present to the skin without evidence of extracutaneous disease at the time of diagnosis. It refers to either to cutaneous T-cell lymphoma (CTCL) or cutaneous B-cell lymphoma (CBCL). The primary cutaneous lymphomas are classified according to the WHO-EORTC classification. CTCL constitutes about 65% of all primary cutaneous lymphomas, of which mycosis fungoides is the most prevalent clinical presentation.MedDRA version: 8.1Level: PTClassification code 10028483EUCTR2005-006157-24-DETopoTarget A/S25
进行中（未招募）
不适用
A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in ß-thalassemia patients with severe cardiac iron overload - DFX AutonomyEUCTR2009-018091-34-GRovartis (Hellas) S.A.C.I52